Company profile · Poznan, Poland

Pikralida Sp. z o.o.

Neurology Drug Discovery, CNS Medicinal Chemistry, and Civilizational Diseases of the Elderly · Preclinical small-molecule development

Poznan Adam Mickiewicz University biotech spin-out with named president and a medicinal-chemistry drug-discovery pipeline in CNS and age-related diseases.

Lead
Stanislaw Pikul (verified ↗)
Address
ul. Uniwersytetu Poznanskiego 10, 61-614 Poznan, Poland (source ↗)
Compliance
Not yet on record
Last reviewed
24 Apr 2026 (1mo ago)
Scale
Preclinical small-molecule development
Capabilities
Medicinal Chemistry Drug Discovery · CNS and Neurology Pipeline · Academic Spin-out Operations
Founded
2019
Headcount
1-10
Site and address
Clinical profileSTATUS: VERIFIED APRIL 2026

Stanislaw Pikul

President and Co-Founder

Check official leadership source
Full addressul. Uniwersytetu Poznanskiego 10, 61-614 Poznan, Poland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source

Pikralida contact page listing Uniwersytetu Poznanskiego 10 in Poznan.

Open source
Operating profile

Preclinical small-molecule development

Poznan, Poland. Neurology Drug Discovery, CNS Medicinal Chemistry, and Civilizational Diseases of the Elderly. Review completed on 24 Apr 2026.

2026 technical specializationNeurology Drug Discovery, CNS Medicinal Chemistry, and Civilizational Diseases of the Elderly
Core capabilities
Medicinal Chemistry Drug DiscoveryCNS and Neurology PipelineAcademic Spin-out Operations
Governance

Polish Office for Registration of Medicinal Products and EMA for future oversight

Public president disclosure, Adam Mickiewicz University spin-out, R&D collaborations documentation

Editorial note

Neurology Drug Discovery, CNS Medicinal Chemistry, and Civilizational Diseases of the Elderly

Poznan Adam Mickiewicz University biotech spin-out with named president and a medicinal-chemistry drug-discovery pipeline in CNS and age-related diseases.

Editorial note

Pikralida is a Poznan academic spin-out with a named president, medicinal-chemistry workflow for CNS targets, and documented university collaborations.

FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026Last reviewed: 24 April 2026
Capabilities

Core capabilities

Primary declared technical activities and areas of operating focus.

Medicinal Chemistry Drug Discovery
CNS and Neurology Pipeline
Academic Spin-out Operations
Verification source dossier

Verification source dossier

Official source set used to support leadership, physical-site, certification, and watch-note evidence.

Leadership evidencePikralida corporate article naming Stanislaw Pikul as President and Co-founder.Source origin: pikralida.euOpen source
Supporting evidencePikralida LinkedIn company page.Source origin: linkedin.comOpen source
Physical-site evidencePikralida contact page listing Uniwersytetu Poznanskiego 10 in Poznan.Source origin: pikralida.euOpen source
Infrastructure

Declared infrastructure

Medicinal chemistry workflow
CNS target discovery
Academic partnership network
Regulatory posture

Quality system coverage

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
REVIEW IN PROGRESS 2026
GLP
REVIEW IN PROGRESS 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026
Verification history

Verification history

24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ

Frequently asked questions

Where is Pikralida Sp. z o.o. located?
Pikralida Sp. z o.o. operates from ul. Uniwersytetu Poznanskiego 10, 61-614 Poznan, Poland, Poznan, Poland.
Who runs Pikralida Sp. z o.o.?
Pikralida Sp. z o.o. is led by Stanislaw Pikul, President and Co-Founder. Verified 24 Apr 2026.
What does Pikralida Sp. z o.o. do?
Poznan Adam Mickiewicz University biotech spin-out with named president and a medicinal-chemistry drug-discovery pipeline in CNS and age-related diseases. Core capabilities: Medicinal Chemistry Drug Discovery, CNS and Neurology Pipeline, Academic Spin-out Operations.
Editorial context

Related technical briefs

Briefs that name Poznan as a covered market or city.